secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010286
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports FY2022 net loss of $81.8M; cash $113.4M; clinical progress across three trials
--------------------------------------------------------------------------------

- Net loss $25.3M in Q4 2022 ($14.7M in Q4 2021); full-year loss $81.8M vs $41.6M in 2021.
- Cash, equivalents, and investments $113.4M at Dec 31, 2022, down from $175.7M a year earlier.
- R&D expense $62.7M in FY2022 vs $28.0M; increase driven by clinical/preclinical development of BMF-219 and BMF-500.
- BMF-219 advanced in three trials: COVALENT-101 (liquid tumors), COVALENT-102 (KRAS-mutant solid tumors), COVALENT-111 (type 2 diabetes); initial diabetes data reported March 2023.
- IND for BMF-500 (FLT3 inhibitor) on track for H1 2023; third development candidate from FUSION platform expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/0000950170-23-010286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/bmea-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer